Top Markets
Coin of the day
Armata Pharmaceuticals, Inc. Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc.

ARMP
Rank in Stocks #18283
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology... Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Share Price
$5.59
Last synced: 2026-09-02
Market Cap
$205.21M
Change (1 day)
6.27%
Change (1 year)
86.33%
Country
US
Trade Armata Pharmaceuticals, Inc. (ARMP)

Category

P/S ratio for Armata Pharmaceuticals, Inc. (ARMP)
P/S ratio as of 2026 TTM: 0
According to Armata Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Armata Pharmaceuticals, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH